Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.51 |
| ▸ | CTSD | P07339 | 12/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3350195 | 1.00 | BACE1 (0.51) | BACE1BACE2CTSDADRB1 | |
| SCHEMBL3352412 | 0.84 | BACE1 (0.54) | BACE1BACE2CTSDADRB1 | |
| SCHEMBL3902724 | 0.79 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL3353339 | 0.79 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL3353346 | 0.79 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL13307750 | 0.78 | BACE1 (0.60) | BACE1BACE2CTSD | |
| SCHEMBL5387700 | 0.76 | BACE1 (0.52) | BACE1BACE2CTSDADRB1 | |
| SCHEMBL5387696 | 0.76 | BACE1 (0.52) | BACE1BACE2CTSDADRB1 | |
| SCHEMBL3354358 | 0.75 | CTSD (0.55) | BACE1CTSD | |
| SCHEMBL3354362 | 0.75 | CTSD (0.55) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.